Search research articles
Contact Us
Filters
Showing results (261-270 of 272) with videos related to
Page
of 28
Sort By:
BMJ Oncology
|
June 23, 2025
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)
Alberto Puccini, Giuseppe Viscardi, Oriana Ciani, et al.
Cancers
|
October 23, 2021
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study
Daniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, et al.
BMC Cancer
|
February 10, 2016
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)
Antonio Avallone, Maria Carmela Piccirillo, Luigi Aloj, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2019
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
Francesco Perrone, Michelino De Laurentiis, Sabino De Placido, et al.
Journal of Cancer Policy
|
January 14, 2026
Defining the Role and Competencies of the Medical Oncologist in Diagnostic and Therapeutic Care Pathways: Consensus Recommendations from the Italian Association of Medical Oncology (AIOM)
Rossana Berardi, Francesca Rossi, Valentina Tarantino, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 31, 2021
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial
Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, et al.
Journal of Translational Medicine
|
October 22, 2021
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 26, 2024
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]"
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Journal of Translational Medicine
|
October 22, 2020
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
Lancet (London, England)
|
November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
Quincy Chu, Francesco Perrone, Laurent Greillier, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 272) with videos related to
Sort By:
Page
of 28
BMJ Oncology
|
June 23, 2025
Patient-reported outcomes (PROs) in clinical trials and in clinical practice: report from the XXI national conference of the Italian Association of Medical Oncology (AIOM)
Alberto Puccini, Giuseppe Viscardi, Oriana Ciani, et al.
Cancers
|
October 23, 2021
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study
Daniela Califano, Daniela Gallo, Gian Luca Rampioni Vinciguerra, et al.
BMC Cancer
|
February 10, 2016
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)
Antonio Avallone, Maria Carmela Piccirillo, Luigi Aloj, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2019
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial
Francesco Perrone, Michelino De Laurentiis, Sabino De Placido, et al.
Journal of Cancer Policy
|
January 14, 2026
Defining the Role and Competencies of the Medical Oncologist in Diagnostic and Therapeutic Care Pathways: Consensus Recommendations from the Italian Association of Medical Oncology (AIOM)
Rossana Berardi, Francesca Rossi, Valentina Tarantino, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 31, 2021
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial
Raimondo Di Liello, Laura Arenare, Francesco Raspagliesi, et al.
Journal of Translational Medicine
|
October 22, 2021
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 26, 2024
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]"
Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.
Journal of Translational Medicine
|
October 22, 2020
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, et al.
Lancet (London, England)
|
November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial
Quincy Chu, Francesco Perrone, Laurent Greillier, et al.
Page
of 28